STOCK TITAN
  1. Home
  2. News
  3. PTCT

Ptc Therapeutics - PTCT STOCK NEWS

Welcome to our dedicated page for Ptc Therapeutics news (Ticker: PTCT), a resource for investors and traders seeking the latest updates and insights on Ptc Therapeutics stock.

PTC Therapeutics (PTCT) provides critical updates through this centralized news resource for investors and industry stakeholders. Track official announcements spanning clinical trial progress, regulatory milestones, and strategic partnerships in rare disease therapeutics.

Access timely updates on PTCT's small molecule developments, gene therapy advancements, and financial disclosures. Our curated feed ensures comprehensive coverage of material events including FDA submissions, research collaborations, and commercialization efforts.

This repository features verified press releases covering:

• Clinical trial results for neuromuscular and oncology programs
• Regulatory filings and orphan drug designations
• Strategic alliances with research institutions
• Financial performance and earnings communications

Bookmark this page for direct access to PTCT's evolving developments in post-transcriptional control therapeutics. Monitor breakthrough innovations addressing Duchenne muscular dystrophy, genetic disorders, and underserved patient populations.

News

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
PTC Therapeutics, Inc. (PTCT) approved non-statutory stock options and restricted stock units for six new employees on Feb. 15, 2024. The awards were granted as part of the new hires' compensation packages. Stock options have an exercise price of $25.69 per share and a 10-year term, while RSUs vest over four years. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.96%
Tags
none
-
News

PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results

Rhea-AI Summary
PTC Therapeutics, Inc. (PTCT) will host a webcast conference call to report Q4 and full year 2023 financial results and discuss business outlook on Feb. 29, 2024, at 4:30 p.m. EST. Participants can access the call via phone or webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.6%
Tags
conferences earnings
-
News

CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna™ (ataluren) Following Re-examination Procedure

Rhea-AI Summary
PTC Therapeutics, Inc. received a negative opinion from the CHMP of the EMA regarding the conditional marketing authorization of Translarna™ for nonsense mutation Duchenne Muscular Dystrophy. The decision has disappointed the company and will result in the withdrawal of the therapy for patients in Europe. The CEO expressed concern for the patients and emphasized that the therapy is safe and effective, and that the decision goes against the wishes of the patient community and expert physicians. The European Commission has 67 days to adopt the opinion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.46%
Tags
none
News

PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
PTC Therapeutics, Inc. (NASDAQ: PTCT) reported unaudited 2023 total revenue of $946 million, showing 35% year-over-year growth. Regulatory filings for sepiapterin in PKU remain on track for 2024, with multiple study readouts planned for 2024, including 12-month interim data from the PIVOT-HD study of PTC518 in HD patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.49%
Tags
none
-
News

PTC Therapeutics to Participate at 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
PTC Therapeutics, Inc. (NASDAQ: PTCT) will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference on Jan. 8, 2024. The presentation will be webcast live on the company's website and archived for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.89%
Tags
conferences
-
News

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
PTC Therapeutics, Inc. (NASDAQ: PTCT) approved non-statutory stock options and restricted stock units for two new employees on Dec. 10, 2023. The stock options have an exercise price of $26.39 per share, with a 10-year term and vesting over four years. The RSUs will also vest over four years, with 25% of the original shares vesting on each annual anniversary of the employee's new hire date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
none
News

PTC Therapeutics Provides Updates on Translarna™ Regulatory Activities

Rhea-AI Summary
PTC Therapeutics, Inc. (NASDAQ: PTCT) provides an update on the regulatory activities for Translarna™ (ataluren) in Europe and the United States. The company has submitted a briefing document for the re-examination of the initial CHMP negative opinion on the renewal of conditional marketing authorization of Translarna in Europe. In the U.S., PTC participated in a Type C meeting with the FDA to discuss a potential path to resubmitting a New Drug Application for Translarna. The company expects a follow-up meeting with the FDA in the first quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.73%
Tags
none
-
News

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
PTC Therapeutics, Inc. approved non-statutory stock options and restricted stock units (RSUs) for 21 new employees. The stock options have an exercise price of $18.45 per share and a 10-year term, vesting over four years. The RSUs vest over four years as well. The grants were made as an inducement for the new hires' employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.51%
Tags
none
-
News

PTC Therapeutics Provides Corporate Update and Reports Third Quarter Financial Results

Rhea-AI Summary
PTC Therapeutics announces Q3 2023 financial results and corporate update
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.71%
Tags
earnings
News

PTC Therapeutics Announces Evrysdi® Royalty Agreement with Royalty Pharma for Up To $1.5 Billion

Rhea-AI Summary
PTC Therapeutics agrees to monetize up to $1.5 billion of the Evrysdi royalty stream with Royalty Pharma
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.98%
Tags
none
Stock PTCT logo
Ptc Therapeutics

Nasdaq:PTCT

PTCT Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

PTCT Stock Data

3.56B
76.86M
2.46%
100%
4.8%
Biotechnology
Pharmaceutical Preparations
Link
United States
WARREN